Clinical Trials | January 04, 2026
FDA nod to first new motion sickness drug in 40 years
The approval is supported by data from three pivotal clinical trials
The approval is supported by data from three pivotal clinical trials
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The accelerated review covers WCK 5222 for multiple critical infections
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Applications include detailed scientific rationale and supporting clinical evidence
Subscribe To Our Newsletter & Stay Updated
